Editas Medicine develops CRISPR-based gene editing medicines for serious diseases from Cambridge, Massachusetts. EDIT reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for EDIT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EDIT is in one of them and how their past EDIT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Editas Medicine
Editas Medicine is a gene editing company based in Cambridge, Massachusetts. It develops medicines that use CRISPR technology to edit DNA inside the body, aiming to treat serious diseases, and its lead experimental candidate targets high cholesterol. The company also licenses its gene editing technology to partners such as Bristol Myers Squibb and Vertex Pharmaceuticals, which use it for medicines in other therapeutic areas.
